Lexaria Bioscience Raises $4M in Strategic Stock Offering for Drug Delivery Tech

Lexaria Bioscience Corp., a global innovator in drug delivery platforms trading on NASDAQ under tickers LEXX and LEXXW, has announced a significant $4 million capital raise through a strategic financing arrangement. The company entered into a definitive agreement for a registered direct offering of 2,666,667 shares of common stock priced at $1.50 per share, representing an at-the-market transaction under Nasdaq rules. In a concurrent private placement, Lexaria will issue unregistered warrants to purchase up to an additional 2,666,667 shares with an exercise price of $1.37 per share, immediately exercisable and expiring five years from the effectiveness of the resale registration statement. H.C. Wainwright & Co. is serving as the exclusive placement agent for this sophisticated financial transaction, which is expected to close around September 29, 2025, pending customary closing conditions.

The offering structure demonstrates Lexaria's strategic approach to capital formation, with the registered direct offering conducted under an effective SEC shelf registration statement (Form S-3, File No. 333-284407) declared effective on January 30, 2025. Investors can access detailed information through the SEC's official website at www.sec.gov, where the prospectus supplement and accompanying documents will be filed. The company plans to utilize the approximately $4 million in gross proceeds, before placement agent fees and offering expenses, for working capital and general corporate purposes. This financing comes at a crucial time for Lexaria as it continues to advance its proprietary DehydraTECH™ drug delivery platform, which improves oral drug absorption and has shown potential for enhanced blood-brain barrier penetration across various pharmaceutical applications.

Lexaria's DehydraTECH technology represents the core of the company's value proposition, with 50 patents granted worldwide and additional patents pending. The platform has demonstrated capabilities in increasing bio-absorption while reducing side effects for orally delivered drugs. The capital infusion from this offering will support the company's ongoing research initiatives and operational needs as it navigates the complex pharmaceutical development landscape. Investors and stakeholders can find additional information through the company's official website at www.lexariabioscience.com or by contacting investor relations. This financing round, announced through www.newmediawire.com, positions Lexaria to continue its innovation in drug delivery systems while maintaining compliance with securities regulations governing both registered offerings and private placements under Section 4(a)(2) of the Securities Act.